光子计数CT细胞外容积分数评估肝纤维化的验证研究
本研究前瞻性纳入139例疑诊肝脏恶性肿瘤患者,均接受光子计数CT(PCCT)和MRI检查。以组织病理学为参考标准,比较PCCT衍生的细胞外容积分数(ECV)与MR弹性成像肝硬度测量(LSM)的诊断效能。结果显示ECV与LSM强相关,且两者对肝纤维化分期诊断效能相当。
要点
- PCCT-ECV与MR弹性成像LSM强相关(ρ=0.84),两种技术诊断效能相当。
- PCCT-ECV对≥F2、≥F3和F4纤维化的AUC分别为0.99、0.98和0.98。
- PCCT-ECV在合并脂肪变性、炎症或BMI≥25的亚组中与病理分期一致性良好。
核心结论
- PCCT衍生的ECV与MR弹性成像衍生的LSM强相关,对肝纤维化分期具有等效且临床可行的诊断效能。
研究设计与样本
- 前瞻性队列研究,2024年7月至2025年7月在瑞金医院连续纳入157例疑诊肝脏恶性肿瘤患者,最终139例入组。
- 所有参与者均接受PCCT和MRI检查,以组织病理学结果为参考标准进行肝纤维化分期。
- 对体重指数≥25及合并脂肪变性或炎症的参与者进行了亚组分析,同时进行相关性、ROC和等效性分析。
关键影像表现/征象
- PCCT测量的ECV与MR弹性成像LSM在个体内水平呈强相关(Spearman ρ = 0.84;P < .001)。
- 合并脂肪变性或炎症以及BMI≥25的亚组中,ECV与组织病理学分期的加权κ系数均≥0.86。
诊断标准与关键数值
- 以组织病理学为参考标准,ECV诊断≥F2、≥F3和F4纤维化的AUC分别为0.99、0.98和0.98,95%CI分别为0.98-1.00、0.96-1.00和0.96-1.00。
- 等效性分析显示ECV与LSM诊断效能相当,≥F2、≥F3和F4的AUC差值95%CI分别为0.005-0.055、-0.015-0.027和-0.021-0.012。
临床应用与阅片要点
- PCCT-ECV可作为肝纤维化分期的一种替代性定量影像生物标志物,与MR弹性成像诊断效能相当。
- 在合并脂肪变性、炎症或BMI≥25的人群中,PCCT-ECV与病理分期一致性仍保持良好,提示适用性较广。
- 临床阅片时可参考ECV数值辅助判断纤维化严重程度,但需结合具体截断值和医院设备条件。
局限性
- 本研究为单中心前瞻性设计,入组对象为疑诊肝脏恶性肿瘤患者,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Photon-counting CT (PCCT) can theoretically be used to quantify extracellular volume fraction (ECV) for liver fibrosis assessment, but its performance remains unclear. Purpose To determine the feasibility of PCCT-derived ECV for staging liver fibrosis by assessing its correlation with MR elastography-derived liver stiffness measurement (LSM) and comparing their diagnostic performance, using histopathologic findings as the reference standard. Materials and Methods Between July 2024 and July 2025, 157 participants with suspected hepatic malignancies were prospectively enrolled and underwent PCCT and MRI at Ruijin Hospital. Intraparticipant comparisons of ECV and LSM were performed, and their diagnostic performance in staging liver fibrosis was evaluated using histopathologic findings as the reference standard. Subgroup analyses of fibrosis staging using ECV were performed among participants with coexisting steatosis or inflammation and participants with a body mass index of 25 or higher. Correlation, receiver operating characteristic, and equivalence analyses were performed. Results Ultimately, 139 participants (mean age, 62 years ± 8 [SD]; 114 male) were included. ECV was strongly correlated with LSM (Spearman ρ = 0.84; P < .001) in an intraparticipant-level comparison. When histopathologic examination was used as the reference standard, the area under the receiver operating characteristic curve (AUC) values for ECV were 0.99 (95% CI: 0.98, 1.00), 0.98 (95% CI: 0.96, 1.00), and 0.98 (95% CI: 0.96, 1.00) for participants with fibrosis stages F2 or higher, F3 or higher, and F4, respectively. Equivalence analysis revealed comparable diagnostic performance between ECV and LSM (95% CI differences in AUCs: 0.005, 0.055 for stage F2 or higher; -0.015, 0.027 for stage F3 or higher; and -0.021, 0.012 for stage F4). With use of the cutoffs derived from the whole-group analysis, ECV showed excellent agreement with histopathologic stage overall and across each subgroup (all weighted κ coefficients ≥0.86; P < .001 for all). Conclusion PCCT-derived ECV was strongly correlated with MR elastography-derived LSM and showed equivalent, clinically feasible performance for liver fibrosis staging. © RSNA, 2026 Supplemental material is available for this article. See also the editorial by Wu and Shi in this issue.
引用
- Wu, Li, Deng, et al. Photon-counting CT Extracellular Volume Fraction for Liver Fibrosis Assessment: Validation against MR Elastography and Histopathology. Radiology. 2026. PMID: 42550028. doi:10.1148/radiol.253979
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。